A prior study of gene expression in lymphoma cells indicated a ∼25% overlap of genes induced by either BET inhibitors or HDAC inhibitors and suggested that the mechanism of synergy of BET plus HDAC inhibition in MYC-overexpressing cells is partly due to induction of HDAC-silenced genes [64]. The gene discussed is HDAC9; the disease is lymphoma.